Novartis Starts Review of Generic-Drug Unit

The transcript discusses Novartis' financial performance, recovery from COVID-19 impacts, and strategic focus on innovative medicines and technologies. It highlights the development of COVID treatments, including vaccines and therapeutics, and the company's partnership with Molecular Partners. The discussion also covers Novartis' strategy for its generic business, Sandoz, and the potential for separation. The transcript concludes with insights into supply chain resilience and the future management of healthcare systems amid potential COVID variants.

What future opportunities does the speaker see for Sandoz in the generic medicines sector?

What challenges did the speaker mention regarding the treatment of non-communicable diseases during the pandemic?

How has Novartis managed supply chain pressures during the pandemic?